Abstract
Tramadol® (analgesic of the landing 2) is a centrally acting analgesic with a dual mode of action. Its analgesic efficacy is attributed to its partial affinity for the (μ) mu-opiate receptor and its inhibition of noradrenaline and serotonin reuptake. Acting in a synergistic manner and being more efficacious, Tramadol® is used worldwide for the treatment of moderate to severe acute or chronic pain. If psychotropics are not an exceptional one because of SIADH (syndrome Inappropriate secretion of antidiuretic hormone), analgesics are not usually. This is the case of Tramadol®. We report on this observation the case of a 22 year old patient hospitalized for poisoning Tramadol®, having presented, hyponatremia, hypoglycemia, rhabdomyolyse and left cardiac decompensation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
